DEVICE: MRDx BCR-ABL Test (B60290100280)

Device Identifier (DI) Information

MRDx BCR-ABL Test
901-0028
In Commercial Distribution
901-0028
MOLECULARMD CORP.
B60290100280
HIBCC

1
784311032 *Terms of Use
The MRDx Test utilizes quantitative, real-time reverse transcription polymerase chain reaction (RT-qPCR) for BCR-ABL and ABL quantitation. The rapid, one-step protocol allows for both reverse transcription and quantitative PCR reactions to be performed in the same well. This provide the advantage of increase sensitivity while limiting experimental variables and also reducing time and cost. The MRDx BCR-ABL Test uses BCR-ABL and ABL standard curves to determine BCR-ABL and ABL copy numbers. The assay has been harmonized to the WHO primary standards for determination of Major Molecular Response (MMR) levels based on the International Scale (IS). Major Molecular Response (MMR) or MR3, defined as greater than or equal to a 3-log reduction in the ration of BCR-ABL/ABL from a standardized baseline value, reflects a patient's response to treatment. In addition, the MRDx BCR-ABL Test includes MR4.5 to enable quantification to 0.0032% IS, which is greater than a 4-log reduction, important for treatment discontinuation and for monitoring of treatment-free remission.
CLOSE

Device Characteristics

Labeling does not contain MRI Safety Information
No
No
Yes
Yes
No
Yes
No
No

GMDN

[?]

GMDN© Term Code, Names and Definitions (*Terms of Use): GMDN® is a registered trademark of The GMDN Agency. All rights reserved. Used under licence from The GMDN Agency Ltd.

GMDN Term Code GMDN Term Name GMDN Term Definition GMDN Term Status [?] Implantable?
44431 Philadelphia chromosome/BCR-ABL mRNA expression IVD, kit, nucleic acid technique (NAT)
A collection of reagents and other associated materials intended to be used for the qualitative and/or quantitative detection of mRNA expression of the Philadelphia chromosome, resulting from translocation t(9;22)(q34; q11) and rearrangement of the BCR and ABL genes, to diagnose, monitor or predict chronic myeloid leukaemia (CML) and/or a subset of acute lymphoblastic leukaemia (ALL) in a clinical specimen, using a nucleic acid technique (NAT).
Active false
CLOSE

FDA Product Code

[?]
Product Code Product Code Name
OYX Bcr/Abl1 Monitoring Test
CLOSE

FDA Premarket Submission

FDA Premarket Submission Number [?] Supplement Number [?]
K173492 000
No CLOSE

Sterilization

No
No
Sterilization Method [?]
No Sterilization Methods Found
CLOSE

Storage and Handling

[?]
Storage and Handling
Storage Environment Temperature: between -85 and -15 Degrees Celsius
CLOSE

Clinically Relevant Size

[?]
Size Type Text
No Device Sizes
CLOSE

Device Record Status

99642795-6c90-4012-adca-5328544658ba
October 06, 2020
3
March 07, 2018
CLOSE

Alternative and Additional Identifiers Additional Identifiers

Package DI

[?]
Package DI Number Quantity per Package Contains DI Package Package Discontinue Date Package Status Package Type
No Package DIs found
CLOSE

Secondary DI

[?]
Issuing Agency [?] Secondary DI Number
No Secondary DIs found
CLOSE

Unit of Use DI

[?]
Unit of Use DI Number: No Unit of Use DI Numbers Found CLOSE

Direct Marking (DM)

[?]
No
No
None
CLOSE

Production Identifier(s) in UDI

[?]
Yes
No
Yes
No
No CLOSE

Customer Contact

[?]
No Customer Contact currently defined
CLOSE